Tu et al. [46] reported that S100A9+CD14+ monocytes contribute to resistance to anti-PD-1 immunotherapy in advanced HCC by dampening T cell-mediated antitumor activity, while our findings imply that CD14 on Mo MDSC may reduce the risk of HCC. This evidence concerns the gene S100A9 and hepatocellular carcinoma.